pois toughest year maintain
fve control pipelin
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data jan
rate updat jan
currenc amount express
methodolog valu compani
maintain fair valu estim amgen
follow in-lin result disappoint guidanc
slightli reduc sale forecast
legaci product reflect steep
competit price pressur larg maintain
forecast newer brand portfolio
increas biosimilar portfolio
assumpt howev cost control key
valuat despit heavi biosimilar pressur neulasta
epogen oper expens pois stay
rel flat minim oper margin pressur
allow see posit ep growth
help share repurchas
share recent trade slight discount
valuat think wide moat remain
support core product prolia/xgeva newer launch
repatha cholesterol lower aimovig migrain
earli pipelin multipl oncolog program asthma
drug tezepelumab enbrel sensipar patent litig
remain risk valuat although alreadi
substanti declin sensipar built model
patent settlement
acceler double-digit declin remaind
forecast enbrel due brand competit
upsid aimovig estim remain consensu
launch acceler exceed estim
could increas valuat addit sever early-stag
oncolog trial read includ once-weekli
bcma-target biolog could boost long-
neulasta face two biosimilar competitor unit
state far -- fulphila coheru
udenyca -- potenti third end year list
price fulphila udenyca third lower
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
leader biotechnology-bas human therapeut
histor expertis renal diseas cancer support care product
flagship drug includ red blood cell booster epogen aranesp immun
system booster neulasta enbrel inflammatori
diseas introduc first cancer therapeut vectibix
receiv approv bone-strengthen drug prolia/xgeva
acquisit onyx bolster firm therapeut oncolog
portfolio nexavar kyproli recent launch includ repatha
cholesterol-low aimovig migrain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
neulasta neulasta discount on-bodi
deliveri system market make biosimilar
slightli less compel increas neulasta
declin base initi traction
fulphila cautiou commentari overal
price commentari estim mid-single-digit
price pressur portfolio epogen
face retacrit biosimilar offer
similar discount neulasta biosimilar epogen
contract offer mitig
potenti volum declin epogen
sale also includ stage price declin
detail patent exposur pipelin
pleas see recent healthcar observ annual drug
pipelin report moat remain secur innov
counter price gener headwind
acceler report also discuss view large-
scale industri cash balanc
billion strong free cash flow gener give
mean take action lacklust intern growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
